Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study of patients treated with BFM therapy

BMC Blood Disorders

Volumn 1, Issue , 2001, Pages

  Stanulla, Martin ^a   Schrauder, André ^a   Welte, Karl ^a   Schrappe, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; LYMPHOTOXIN; MERCAPTOPURINE; METHOTREXATE; NUCLEOTIDE; PREDNISONE; TIOGUANINE; TUMOR NECROSIS FACTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CHILD CARE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRE B LYMPHOCYTE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SOLID TUMOR; TREATMENT FAILURE;

EID: 0005510896     PISSN: 14712326     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2326-1-2     Document Type: Article

References (18)

1. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334:1717-1725
2. Warzocha K, Bienvenu J, Coiffier B, Salles G: Mechanism of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Eur Cytokine Network 1995, 6:83-96
3. Dosquet C, Coudert M C, Le page E, C abane J, Richard F : Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997, 3:2451-2458
4. Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, Coiffier B, Salles G: Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 1998, 77:2357-2362
5. Kobayashi D, Watanabe N, Yamauchi N, Tsuji N, Sato T, Niitsu Y: Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemia patients. Blood 1997, 89:2472-2479
6. Warzocha K , Salles G, B ienvenu J, Bastion Y , Dumontet C , Renard N , Neidhardt EM, Coiffier B: The tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 1997, 15:499-508
7. Wilson AG, di Giovine FS, Blakemore AIF, Duff GW: Single base polymorphism in the human tumor necrosis factor alpha (TNFa) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992, 1:353-
8. Abraham LJ, Kroeger KM: Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. JLeukoc Biol 1999, 66:562-566
9. Messer G, Spengler U, Jung MC, Honold G, Blömer K, Pape GR, Riethmüller G, Weiss EH: Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNFbeta production. J Exp Med 1991, 173:209-219
10. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B, Salles G: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998, 91:3574-3581
11. Wilson A G, di Giovine FS, D uff G W: Genetics of tumor necrosis factor-α in autoimmune, infectious, and neoplastic diseases. J Inflamm 1995, 45:1-12
12. Nadel S, Newport M J, Booy R, L evin M: Variation in the tumor necrosis factor-α gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996, 174:878-880
13. Stüber F, Petersen M, Bokelmami F, Schade U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996, 24:381-384
14. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, Convit J, Blackwell JM: Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995, 182:1259-1264
15. Demeter J, Porzsolt F: Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol 1997, 97:107-112
16. Reiter A, Schrappe M , Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994, 84:3122-3133
17. Schrappe M , Reiter A, Ludwig W-D, H arbott J, Zimmermann M, Hiddemann W, Niemeyer CM, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H: Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000, 95:3310-3322
18. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K: Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 2000, 95:1222-1228